Cat. No.: HY-100746

STF-62247

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

STF-62247 is an autophagy inducer that selectively cytotoxic to VHL-deficient renal cell carcinoma (IC₅₀ of 0.625 μM and 16 μM in RCC4 and RCC4/VHL cells, respectively).

For research use only. We do not sell to patients.

Purity: 98.69%
CAS No.: 315702-99-9
Formula: C₁₅H₁₃N₃S
Molecular Weight:267.35

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

STF-62247 Chemical Structure

CAS No.: 315702-99-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

STF-62247 is an autophagy inducer that selectively cytotoxic to VHL-deficient renal cell carcinoma (IC₅₀ of 0.625 μM and 16 μM in RCC4 and RCC4/VHL cells, respectively)^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
786-0	IC₅₀	5.7 μM Compound: 3; STF-62247	Cytotoxicity against VHL-deficient human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-deficient human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
786-0	IC₅₀	6.9 μM Compound: 3; STF-62247	Cytotoxicity against VHL-positive human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-positive human 786-0 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
RCC4	GI₅₀	2.1 μM Compound: 11	Growth inhibition of VHL-null human RCC4 cells after 4 days by XTT assay Growth inhibition of VHL-null human RCC4 cells after 4 days by XTT assay	[PMID: 19994864]
RCC4	IC₅₀	1.2 μM Compound: 3; STF-62247	Cytotoxicity against VHL-deficient human RCC4 cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-deficient human RCC4 cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]
RCC4	IC₅₀	2.1 μM Compound: 1	Cytotoxicity against human RCC4 cells after 4 days by XTT assay Cytotoxicity against human RCC4 cells after 4 days by XTT assay	[PMID: 24387866]
RCC4	IC₅₀	2.1 μM Compound: 2	Growth inhibition of human RCC4 cells after 4 days by XTT assay Growth inhibition of human RCC4 cells after 4 days by XTT assay	[PMID: 21561782]
RCC4/VHL	IC₅₀	40 μM Compound: 1	Cytotoxicity against human RCC4/VHL cells after 4 days by XTT assay Cytotoxicity against human RCC4/VHL cells after 4 days by XTT assay	[PMID: 24387866]
RCC4/VHL	IC₅₀	40 μM Compound: 2	Growth inhibition of human RCC4/VHL cells after 4 days by XTT assay Growth inhibition of human RCC4/VHL cells after 4 days by XTT assay	[PMID: 21561782]
RCC4/VHL	IC₅₀	5.3 μM Compound: 3; STF-62247	Cytotoxicity against VHL-positive human RCC4/VHL cells assessed as reduction in cell viability incubated for 4 days by XTT assay Cytotoxicity against VHL-positive human RCC4/VHL cells assessed as reduction in cell viability incubated for 4 days by XTT assay	[PMID: 31260889]

In Vitro

In RCC4, RCC4/VHL, SN12C, SN12C-VHL shRNA cells, STF-62247 (0-30 μM) is selectively toxic to VHL-deficient cells compared to their VHL wild-type counterparts^[1].
STF-62247-treated cells accumulated intracytoplasmic vacuoles characteristic of cells undergoing autophagy. Moreover, these vacuoles are larger in VHL-deficient RCC4 and SN12C-VHL shRNA cells than in wild-type VHL cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

STF-62247 (2.7-8 mg/kg; intraperitoneal injection; daily; for 9 days) treatment significantly reduces tumor growth of VHL-deficient cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

SCID mice implanted with SN12C-VHL shRNA cells^[1]
Dosage:

2.7 mg/kg, or 8 mg/kg
Administration:

Intraperitoneal injection; daily; for 9 days
Result:

Significantly reduced tumor growth of VHL-deficient cells.

Chemical Information

CAS No. 315702-99-9
Appearance Solid
Molecular Weight 267.35
Formula C₁₅H₁₃N₃S
Color Light yellow to yellow
SMILES

CC1=CC(NC2=NC(C3=CC=NC=C3)=CS2)=CC=C1
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

J Nanobiotechnology

Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA. [Abstract]

2023 Oct 3;21(1):360. PMID: 37789342
Cell Rep Med

HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer. [Abstract]

2026 Feb 18:102630. PMID: 41713410

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (187.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7404 mL

18.7021 mL

37.4041 mL

5 mM

0.7481 mL

3.7404 mL

7.4808 mL

10 mM

0.3740 mL

1.8702 mL

3.7404 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Turcotte, S. et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer cell 14, 90-102, doi:10.1016/j.ccr.2008.06.004 (2008) [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7404 mL	18.7021 mL	37.4042 mL	93.5104 mL
	5 mM	0.7481 mL	3.7404 mL	7.4808 mL	18.7021 mL
	10 mM	0.3740 mL	1.8702 mL	3.7404 mL	9.3510 mL
	15 mM	0.2494 mL	1.2468 mL	2.4936 mL	6.2340 mL
	20 mM	0.1870 mL	0.9351 mL	1.8702 mL	4.6755 mL
	25 mM	0.1496 mL	0.7481 mL	1.4962 mL	3.7404 mL
	30 mM	0.1247 mL	0.6234 mL	1.2468 mL	3.1170 mL
	40 mM	0.0935 mL	0.4676 mL	0.9351 mL	2.3378 mL
	50 mM	0.0748 mL	0.3740 mL	0.7481 mL	1.8702 mL
	60 mM	0.0623 mL	0.3117 mL	0.6234 mL	1.5585 mL
	80 mM	0.0468 mL	0.2338 mL	0.4676 mL	1.1689 mL
	100 mM	0.0374 mL	0.1870 mL	0.3740 mL	0.9351 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

STF-62247

Anti-Cancer Compound Library

Autophagy Compound Library

Heterocyclic Compound Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) STF-62247

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

STF-62247

Anti-Cancer Compound Library

Autophagy Compound Library

Heterocyclic Compound Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) STF-62247

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

STF-62247 Related Classifications

HY-100746 Related Classifications